Reviews
Comparative Overall Survival and Toxicity of Radiosensitising Strategies in Locally Advanced HNSCC
Sreeram et alEClinicalMedicine

In the systematic review and network meta-analysis of randomised controlled trials (RADIANCE-NMA), investigators evaluated concurrent radiosensitising regimens in adult patients with locally advanced head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma). The primary outcome was overall survival (OS). The primary analysis evaluated 44 Phase IIb–III trials comprising 13,768 patients (84% male), with 23 additional trials incorporated into sensitivity analyses (totalling 67 trials and 19,527 patients). Risk of bias assessed via the Cochrane RoB 2 tool identified some concerns in 39 of the 44 primary trials (89%).
Four treatment strategies showed significant overall survival benefit compared to radiotherapy alone: cisplatin plus 5-fluorouracil (hazard ratio [HR] 0.35; 95% confidence interval [CI] 0.18–0.66), nimotuzumab plus weekly cisplatin (HR 0.48; 95% CI 0.29–0.81), weekly cisplatin (HR 0.57; 95% CI 0.44–0.74), and three-weekly cisplatin (HR 0.79; 95% CI 0.65–0.95). In the network estimate, weekly cisplatin was favoured over the three-weekly regimen (HR 0.73; 95% CI 0.58–0.93), with underlying randomised trials designed as non-inferiority comparisons. Between-study heterogeneity was moderate (I² = 48.9%; τ² = 0.036; Cochran Q = 37.15, df = 19, p = 0.008), and no inconsistency was detected (design-by-treatment global test p = 0.88). Funnel plot and Egger's regression test indicated no evidence of small-study effects, interpreted as exploratory due to fewer than ten trials per edge across most comparisons.
Grade 3–4 adverse events were most frequent with weekly cisplatin, showing a pooled toxicity rate of 71.6% across contributing trials, and lowest with immunotherapy combinations. Meta-regression confirmed enrolment era as a significant effect modifier (β = 0.23 post-2005 vs pre-2005; p = 0.010), coinciding with the clinical transition from two-dimensional or conformal radiotherapy to intensity-modulated radiotherapy (IMRT). Neither cetuximab-based regimens nor immune-checkpoint inhibitors added to cisplatin-based chemoradiotherapy significantly improved overall survival compared to standard cisplatin chemoradiotherapy.
Key Takeaways
- Four regimens showed significant overall survival benefit versus radiotherapy alone: cisplatin plus 5-fluorouracil (HR 0.35, 95% CI 0.18–0.66), nimotuzumab plus weekly cisplatin (HR 0.48, 95% CI 0.29–0.81), weekly cisplatin (HR 0.57, 95% CI 0.44–0.74), and three-weekly cisplatin (HR 0.79, 95% CI 0.65–0.95).
- In network estimates, weekly cisplatin was favoured over three-weekly cisplatin for overall survival (HR 0.73, 95% CI 0.58–0.93), though grade 3–4 toxicity was highest with the weekly cisplatin schedule at a pooled 71.6%.
- Neither cetuximab-based regimens nor the addition of immune-checkpoint inhibitors to cisplatin-based chemoradiotherapy significantly improved survival compared with standard cisplatin chemoradiotherapy.
Read the original sourceEClinicalMedicine
